ANAL CANAL UNDIFFERENTIATED CARCINOMA

Clinical trials for ANAL CANAL UNDIFFERENTIATED CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new ANAL CANAL UNDIFFERENTIATED CARCINOMA trials appear

Sign up with your email to follow new studies for ANAL CANAL UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Major trial aims to tame dozens of rare, neglected cancers with immune power combo

Disease control Ongoing

This large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …

Matched conditions: ANAL CANAL UNDIFFERENTIATED CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

ANAL CANAL UNDIFFERENTIATED CARCINOMA

Get alerted when new ANAL CANAL UNDIFFERENTIATED CARCINOMA trials appear

Major trial aims to tame dozens of rare, neglected cancers with immune power combo